Answers are grounded in this paper and cite their sources.
Safety assessment finds increased herpes zoster risk in children vaccinated with SKYVaricella, suggesting need for updated risk management.
ContextSKYVaricella is a live attenuated varicella-zoster virus vaccine, developed by the Korean manufacturer, SK Bioscience.The Ministry of Food and Drug Safety (MFDS) first approved it in 2018, and the World Health Organization (WHO) granted prequalification in 2019.It is currently one of 4 WHO prequalified varicella vaccines.In its phase 3 trial, the vaccine demonstrated immunogenicity non-inferior to Varivax, but it has not been evaluated for protective efficacy, durability of immune response, long-term safety beyond 26 weeks, or adverse events occurring in fewer than 1 in 330 recipients [1].A reported fatal case of disseminated vaccine-virus varicella in a SKYVaricella-vaccinated child prompted a joint safety assessment by the Korea Disease Control and Prevention Agency (KDCA) and the MFDS in 2024 [2].The agencies concluded that SKYVaricella did not cause the fatal case and that no immediate safety concern warranted removal from the National Immunization Program (NIP) [3].However, they identified an increased risk of herpes zoster (HZ) in SKYVaricella-vaccinated children.They announced plans to strengthen risk management, but no detailed risk minimizing actions or follow-up updates in benefit-risk assessment have been released.SK Bioscience updated the vaccine's risk management plan (RMP) in August 2024.The revision removed most of misclassified safety concerns from the initial RMP and added HZ as an important potential risk [4,5].It also introduced educational materials for patients and physicians as additional risk minimization measures (RMMs), although the materials did not describe HZ characteristics in vaccinated children [6].Despite acknowledging the new safety concern in the RMP, the manufacturer has not properly updated the product information and continues to assert that no new safety concern exists [7].Since the KDCA and MFDS press briefing, new evidence has emerged.Kim et al. [8] reported a case series of 23 children who developed HZ after SKYVaricella vaccination between February 2021 and March 2024; 43.4% required hospitalization.At the population level, Lee [9] conducted an ecological study using Korean National Health Insurance Service data and estimated 6,484 excess HZ cases potentially due to SKYVaricella vaccination in Korean children under 5 years of age from January 2019 to June 2024.Although these studies describe the frequency, seriousness, and public health impact of HZ in this population, Korean authorities have not commented on the findings, and it remains unclear whether they have re-evaluated the vaccine's risk-benefit profile in light of this new information.
No takes yet. Share an insight, caveat, or question.
Joowon Lee (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: